Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Adjunctive S-adenosylmethionine (SAMe) in treating non-remittent major depressive disorder: An 8-week double-blind, randomized, controlled trial
European Neuropsychopharmacology, Volume 28, No. 10, Year 2018
Notification
URL copied to clipboard!
Description
There has been increasing interest in nutraceutical augmentation strategies to boost the efficacy of antidepressants. This study assessed whether S-adenosylmethionine (SAMe), a methyl donor that occurs naturally in the body, may be of such benefit. We conducted an 8-week, double-blind RCT in which 107 treatment non-remittent outpatients with DSM-5 diagnosed Major Depressive Disorder (MDD) were randomized to either SAMe or placebo adjunctively to antidepressants. One-carbon cycle nutrients, pertinent single nucleotide polymorphisms (SNPs), and BDNF were also analysed as potential moderators of response. A linear mixed-effects model revealed a significant overall reduction in Montgomery-Asberg Depression Rating Scale (MADRS) score across time, however there was no significant between-group difference observed (p = 0.51). Response rates at Week 8 were 54.3% in the SAMe group and 50.0% in the placebo group, with remission rates 43.5% for SAMe and 38.3% for placebo (all results NS). No effect of SAMe was found on any secondary outcome. Differential response to SAMe was not modified by a range of key genotypes (e.g. COMT), nor reflected in a change of homocysteine, red cell folate, or BDNF. Use of SAMe elicited no significant adverse effects beyond placebo, however it was implicated in one case of serotonin syndrome-like symptoms. This study concludes that 800 mg/day of SAMe is not an effective adjunctive treatment in MDD, and no obvious biomarker reflected any differential response to treatment. Due to such a distinctly high placebo-response (despite rigorous screening), future studies should employ a placebo run-in period and other strategies to minimize placebo response. © 2018
Authors & Co-Authors
Sarris, Jerome
Australia, Penrith
Western Sydney University
Australia, Melbourne
University of Melbourne
Bousman, Chad A.
Canada, Calgary
University of Calgary
Australia, Hawthorn
Swinburne University of Technology
Stough, Con K.K.
Australia, Geelong
Barwon Health
Cribb, Lachlan
Australia, Melbourne
University of Melbourne
Berk, Michael
Australia, Melbourne
University of Melbourne
Australia, Melbourne
The Florey
Australia, Melbourne
Orygen Youth Health
United States, Boston
Harvard Medical School
Ng, Chee H.
Australia, Melbourne
University of Melbourne
Mischoulon, David
United States, Boston
Harvard Medical School
Statistics
Citations: 25
Authors: 7
Affiliations: 9
Identifiers
Doi:
10.1016/j.euroneuro.2018.07.098
ISSN:
0924977X
Research Areas
Disability
Environmental
Mental Health
Substance Abuse
Study Design
Randomised Control Trial
Study Approach
Quantitative